News and Press

Press releases

Diagonal Bio’s CEO Karin Wehlin increases ownership

Non-regulatory

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025.  

Read more

Diagonal Bio AB’s rights issue of units oversubscribed

Regulatory

The subscription period in Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the “Rights Issue”). The Rights Issue was subscribed to a total of approximately 122 percent, including subscription undertakings, meaning that no underwriting commitments have been utilized. In parallel with the Rights Issue, the Company has carried out the directed issue of units which was announced on 23 December 2024 and approved by the Extraordinary General Meeting 17 January 2025, of initially approximately SEK 1.7 million to Redén Trotting AB and Svea Bank AB (the “Directed Issue”). In total, through the Rights Issue and the Directed Issue, Diagonal Bio is thus provided proceeds of approximately SEK 7.7 million before deduction of issue related costs. Should all attached warrants of series TO 2 issued in the Rights Issue and the Directed Issue be exercised, the Company may receive additional proceeds of approximately SEK 3.4 million in June 2025.  

Read more

Stall Goop conducts pilot test of LAMPlify®

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®.  The three-month pilot test, starting in February 2025, aims to enhance equine health and performance by enabling early detection of potential virus infections in horses.

Read more

Diagonal Bio announces positive pilot test results and secures order from StallZet

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of the pilot test which started in October 2024 and includes the purchase of LAMPlify® along with associated consumables.

Read more

The subscription period of Diagonal Bio AB’s rights issue of units commences today

Regulatory

Today, 23 January 2025, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) rights issue of units of initially approximately SEK 6 million, with preferential rights for the Company’s existing shareholders, commences (the “Rights Issue”). The subscription period runs until 6 February 2025. The Rights Issue was resolved upon by the Board of Directors on 23 December 2024 and approved by the Extraordinary General Meeting on 17 January 2025, together with the resolution on a directed issue of units (the “Directed Issue”, together, the Rights Issue and the Directed Issue are referred to as the “Transaction”). The purpose of the Transaction is to provide funds to focus on validation of LAMPlify®’s commercial interest. The Rights Issue is covered by subscription undertakings from the Board members, the CEO, and other shareholders, of in total approximately SEK 0.4 million, corresponding to approximately 6 percent of the Rights Issue. In addition, Diagonal Bio has received underwriting commitments from the Company’s CEO Karin Wehlin, the Board members and a number of external investors of a total of SEK approximately 3 million, corresponding to approximately 50 percent of the Rights Issue, which means that the Rights Issue in total is covered by subscription and underwriting commitments of 56 percent. The Board members and CEO Karin Wehlin have entered into customary lock-up agreements corresponding to 100 percent of their respective shareholdings until 31 July 2025.  

Read more